Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VG161 with or without Nivolumab in HCC and ICC
NCT05223816Phase 2Recruiting
- Sponsor
- Virogin Biotech
- Start
- Jan 2024
- Primary completion
- Oct 2025
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of VG161 in hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), sponsored by Virogin Biotech. Started Jan 2024; status: recruiting.
02
Drugs
VG161
03
Conditions
hepatocellular carcinoma (HCC)intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT05223816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05223816.